Archive for GlennByrd SmartBlogs
This post was written by SmartBrief’s Elizabeth Collins.
The pharmaceutical companies that say they are waiting for the Food and Drug Administration to issue new guidance on how to handle drug promotion through social media are just using the FDA’s guidance delay as an “out,” or an excuse, said Glenn Byrd, MedImmune’s director of regulatory affairs, at the Marcus Evans “Social Media for Pharma” conference in Washington, D.C., on Thursday.[…] Continue Reading »
The health care industry is discovering the opportunities that social media can offer, such as increased patient-physician interaction and service integration. However, this new platform also brings with it some risks — known and unknown — that must be carefully managed. Glenn Byrd heads up the advertising and promotions team at MedImmune. Byrd will be a speaker at the upcoming marcus evans Social Media for Pharma Conference on Jan.[…] Continue Reading »
Twitter
Facebook
Linkedin
RSS
